About universalibstg

This author has not yet filled in any details.
So far universalibstg has created 29 blog entries.

Universal Ibogaine Provides Update on Planned Clinical Trial Application Process

2024-04-30T12:33:44-07:00April 29th, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - April 29, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to provide an update on its planned Clinical Trial Application (“CTA”) process.  UI has engaged a new clinical research organization (“CRO”) to complete the process of compiling UI’s [...]

Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders

2024-04-24T11:13:21-07:00April 22nd, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - April 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 23,333,333 common shares at a price of $0.015 per share, for proceeds of up to $350,000 [...]

Universal Ibogaine Announces New Private Placement Financing

2024-04-12T09:36:54-07:00April 12th, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - April 12, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares at a price of $0.02 per share, for proceeds of up to $600,000 [...]

Universal Ibogaine Announces Closing of Private Placement Financing

2024-04-10T09:19:52-07:00April 10th, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - April 10, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce that it has closed its previously announced (see News Release of February 22) non-brokered private placement offering of common shares (the “Offering”) and has issued 57,557,600 [...]

Universal Ibogaine Advises of Management Change

2024-04-09T11:55:46-07:00April 9th, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - April 8, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that Ian Rabb, Chief Clinics Officer, is no longer with the Company.  Mr. Rabb’s role with the Company’s subsidiary, which operates the Kelburn Recovery Centre (“Kelburn”) addiction treatment facility [...]

Universal Ibogaine Announces Additional Private Placement Financing

2024-02-23T09:45:52-08:00February 22nd, 2024|Universal Ibogaine News|

Calgary, AB – February 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it is undertaking a private placement offering of up to 80,000,000 common shares at a price of $0.01 per share (the “Offering”) for proceeds of up to $800,000. The proceeds [...]

Universal Ibogaine advises of closing of private placement financing

2024-02-15T07:01:28-08:00February 7th, 2024|Universal Ibogaine News|

Calgary, AB – February 7, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce the closing of its previously announced (see news release of December 20, 2023) non-brokered private placement (the “Placement”) of common shares, and has issued 41,719,250 common shares at [...]

Universal Ibogaine provides final Bi-weekly Default Status Report on year-end and Q1 filing

2024-02-06T12:58:31-08:00February 2nd, 2024|Universal Ibogaine News|

Calgary, AB – February 2, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 19, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in [...]

Universal Ibogaine provides Bi-weekly Default Status Report and update on status of Private Placement

2024-01-22T19:19:07-08:00January 19th, 2024|Universal Ibogaine News|

Calgary, AB – TheNewswire - January 19, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 5, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 20, 2023, UI announced that it would delay the filing of its annual audited financial statements for the [...]

Universal Ibogaine provides Bi-weekly Default Status Report

2024-01-22T19:35:29-08:00January 5th, 2024|Ibogaine Blog, Universal Ibogaine News|

Calgary, AB – TheNewswire -- January 5, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news releases (November 20, December 1, December 11, and December 20, 2023), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 20, 2023, UI announced that it would delay the filing of [...]

Go to Top